A detailed history of Perceptive Advisors LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 2,378,762 shares of IMVT stock, worth $65.4 Million. This represents 1.71% of its overall portfolio holdings.

Number of Shares
2,378,762
Previous 1,923,786 23.65%
Holding current value
$65.4 Million
Previous $50.8 Million 28.85%
% of portfolio
1.71%
Previous 1.47%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$27.51 - $27.51 $12.5 Million - $12.5 Million
454,976 Added 23.65%
2,378,762 $65.4 Million
Q2 2024

Aug 14, 2024

SELL
$25.1 - $31.61 $26.1 Million - $32.9 Million
-1,039,426 Reduced 35.08%
1,923,786 $50.8 Million
Q1 2024

May 15, 2024

BUY
$30.27 - $43.79 $19.2 Million - $27.8 Million
635,130 Added 27.28%
2,963,212 $95.7 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $46.5 Million - $65.7 Million
-1,486,609 Reduced 38.97%
2,328,082 $98.1 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $23.9 Million - $51.6 Million
1,290,908 Added 51.15%
3,814,691 $146 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $17.5 Million - $29.3 Million
1,231,925 Added 95.36%
2,523,783 $47.9 Million
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $17.4 Million - $22.5 Million
1,141,858 Added 761.24%
1,291,858 $20 Million
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $988,500 - $2.66 Million
150,000 New
150,000 $2.66 Million
Q1 2021

May 17, 2021

SELL
$13.08 - $49.6 $18.3 Million - $69.4 Million
-1,400,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$22.61 - $38.9 $6.78 Million - $11.7 Million
300,000 Added 27.27%
1,400,000 $49.3 Million
Q2 2020

Aug 14, 2020

BUY
$13.87 - $28.44 $15.3 Million - $31.3 Million
1,100,000 New
1,100,000 $26.8 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.